Today, at the second Global Summit on COVID-19, President Biden announced that the Biden-Harris administration, through the US National Institutes of Health (NIH), has authorized 11 tools for research on COVID-19 and from vaccine candidates and early-stage diagnostics to drugs. Patent Pool (MPP) through the World Health Organization’s COVID-19 Technology Access Pool (C-TAP). The licenses will allow manufacturers around the world to work with MPP and C-TAP to use these technologies for the potential development of COVID-19 vaccines, treatments and diagnostics to benefit people living in low- and middle-income countries. . Licensed technologies include SARS-CoV-2 stabilized spike protein, a patented invention included in several COVID-19 vaccines.
C-TAP aims to stimulate the global supply of vaccines, treatments and diagnostics for COVID-19 by facilitating the sharing of intellectual property, knowledge and data with quality-assured manufacturers who have the capacity to increase the production. NIH scientists routinely make discoveries, whether patented or not, that can be transferred to the private sector for further research and development and eventual commercialization. While the NIH has already granted non-exclusive licenses to companies to use the SARS-CoV-2 stabilized spike protein, making this and other technologies available through C-TAP will facilitate easy access. even wider.
“Controlling COVID-19 globally and addressing future public health threats is only possible if all communities, including the most vulnerable, have access to lifesaving treatments, vaccines and diagnostics” , said Xavier Becerra, Secretary of Health and Human Services. “Sharing our scientific knowledge and health technologies with C-TAP to aid in the development of crucial medical countermeasures is another step we are taking to help our global partners in our common fight against this devastating disease.”
“NIH scientists have developed innovative COVID-19 research tools, vaccines, and diagnostics. Although NIH cannot commercialize these technologies at an early stage, we can share our knowledge where possible to support our global partners,” said NIH Acting Director Lawrence A. Tabak, DDS. “NIH contributions to C-TAP provide a piece of the technology puzzle to help global manufacturers advance the development of diagnostics, vaccines and treatments for COVID-19. I hope the actions of the NIH will inspire other rights holders to do the same.
For more information on NIH technologies, please visit the NIH Office of Technology Transfer website. To read the full licenses, please visit the MPP website.